The smartest insight and analysis, from all perspectives, rounded up from around the web: Two years ago, the blood-testing startup Theranos "was one of the hottest properties in Silicon Valley," said David Crow at the Financial Times. Valued at $9 billion, it promised nothing short of a paradigm shift in medicine with its revolutionary, needle-free test method.